CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
June 18, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
May 24, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 03, 2024 11:23 ET
|
CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
April 26, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
April 24, 2024 10:00 ET
|
CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
Cutaneous Squamous Cell Carcinoma (CSCC) Global Clinical Trials Review 2024: Trial Status, Trial Phase, Sponsor Type, End Point Status, Country (G7 & E7)
April 08, 2024 09:31 ET
|
Research and Markets
Dublin, April 08, 2024 (GLOBE NEWSWIRE) -- The "Cutaneous Squamous Cell Carcinoma (Cscc) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's...
Non-Small Cell Lung Cancer (NSCLC) Epidemiology Forecast to 2032 Across Eight Major Markets (US, France, Germany, Italy, Spain, UK, Japan and Urban China)
April 03, 2024 11:29 ET
|
Research and Markets
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer (NSCLC): Epidemiology Forecast to 2032" report has been added to ResearchAndMarkets.com's offering.Non-small cell lung...
Non-muscle Invasive Bladder Cancer (NMIBC) Epidemiology Forecasts to 2034
January 25, 2024 09:04 ET
|
Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Non-muscle Invasive Bladder Cancer (NMIBC) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The...
Global NSCLC Market Dynamics and Innovations: Striving to Transform Lung Cancer Treatment
September 05, 2023 09:51 ET
|
Research and Markets
Dublin, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company...